Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Holdings Decreased by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp reduced its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,365 shares of the specialty pharmaceutical company’s stock after selling 3,176 shares during the period. Texas Permanent School Fund Corp owned about 0.08% of Collegium Pharmaceutical worth $817,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Principal Securities Inc. purchased a new stake in Collegium Pharmaceutical in the 4th quarter worth approximately $40,000. Dimensional Fund Advisors LP increased its stake in shares of Collegium Pharmaceutical by 2.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock worth $31,987,000 after acquiring an additional 29,529 shares during the last quarter. Assetmark Inc. increased its stake in shares of Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth $338,000. Finally, Avidity Partners Management LP boosted its position in Collegium Pharmaceutical by 3.2% during the fourth quarter. Avidity Partners Management LP now owns 361,363 shares of the specialty pharmaceutical company’s stock valued at $11,123,000 after purchasing an additional 11,163 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.4 %

Shares of Collegium Pharmaceutical stock opened at $39.07 on Friday. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock has a 50 day moving average price of $36.09 and a two-hundred day moving average price of $35.46. The stock has a market capitalization of $1.28 billion, a P/E ratio of 16.28 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. The business had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.13 EPS. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $41.00 to $44.00 in a report on Friday, June 7th. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. Finally, Truist Financial raised their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.